Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention

Lipids in Health and Disease

Shi-Long Zhong³  Shuo Sun¹  Ying Zhang¹  Jun-Qing Yang¹  Zhu-Jun Chen¹  Ying-Ling Zhou¹  Guang Li¹  Zhi-Gen Li² 

[1] Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangdong General Hospital, 96 Dongchuan Road, Guangzhou 510007, China;Department of Geriatrics, Guangzhou First People’s Hospital, Guangzhou Medical University, 1 Panfu Road, Guangzhou 510045, China;Medical Research Center, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangdong General Hospital, 96 Dongchuan Road, Guangzhou 510007, China

关键词: Single-nucleotide polymorphism;    Percutaneous coronary intervention;    Major adverse cardiovascular events;    Lipoprotein(a);    Coronary artery disease;   

Others  :  833868
DOI  :  10.1186/1476-511X-12-127

 received in 2012-08-15, accepted in 2013-08-21,  发布年份 2013

【 摘 要 】

Background

Elevated lipoprotein(a) [Lp(a)] levels predict cardiovascular events incidence in patients with coronary artery disease (CAD). Genetic variants in the rs3798220, rs10455872 and rs6415084 single-nucleotide polymorphisms (SNPs) in the Lp(a) gene (LPA) correlate with elevated Lp(a) levels, but whether these SNPs have prognostic value for CAD patients is unknown. The present study evaluated the association of LPA SNPs with incidence of subsequent cardiovascular events in CAD patients after percutaneous coronary intervention (PCI).

Methods

TaqMan SNP genotyping assays were performed to detect the rs6415084, rs3798220 and rs10455872 genotypes in 517 Chinese Han patients with CAD after PCI. We later assessed whether there was an association of these SNPs with incidence of major adverse cardiovascular events (MACE: cardiac death, nonfatal myocardial infarction, ischemic stroke and coronary revascularization). Serum lipid profiles were also determined using biochemical methods.

Results

Only the rs6415084 variant allele was associated with higher Lp(a) levels [41.3 (20.8, 74.6) vs. 18.6 (10.3, 40.9) mg/dl, p < 0.001]. During a 2-year follow-up period, 102 patients suffered MACE, and Cox regression analysis demonstrated that elevated Lp(a) (≥30 mg/dl) levels correlated with increased MACE (adjusted HR, 1.69; 95% CI 1.13-2.53), but there was no association between LPA genetic variants (rs6415084 and rs3798220) and MACE incidence (p > 0.05).

Conclusions

Our data did not support a relationship between genetic LPA variants (rs6415084 and rs3798220) and subsequent cardiovascular events after PCI in Chinese Han CAD patients.

【 授权许可】

   
2013 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH: Human plasma lipoprotein [a]. Structural properties. J Biol Chem 1983, 258(7):4582-4589.
• [2]Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP: Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996, 276(7):544-548.
• [3]Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T: Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997, 52(5):254-261.
• [4]Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102(10):1082-1085.
• [5]Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301(22):2331-2339.
• [6]Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, Coresh J, Mosley TH, Morrisett JD, Catellier DJ, et al.: Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2012, 125(2):241-249.
• [7]Erqou S, Kaptoge S, Perry PL, Di-Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302(4):412-423.
• [8]Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, Van-Geuns RJ, Boersma E, Van-Domburg RT, Serruys PW: Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. Clin Cardiol 2012, 35(8):482-489.
• [9]Zhou J, Cui X, Jin X, Fu M, Zhong C, Sun A, Hu K, Ge J: Association between Lipoprotein (a) level on admission and the incidence of subsequent cardiovascular events in patients with acute coronary syndrome. Int J Cardiol 2012, 158(3):464-466.
• [10]Nicholls SJ, Tang WH, Scoffone H, Brennan DM, Hartiala J, Allayee H, Hazen SL: Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res 2010, 51(10):3055-3061.
• [11]Chretien JP, Coresh J, Berthier-Schaad Y, Kao WH, Fink NE, Klag MJ, Marcovina SM, Giaculli F, Smith MW: Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. J Med Genet 2006, 43(12):917-923.
• [12]Lanktree MB, Anand SS, Yusuf S, Hegele RA: Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet 2010, 3(1):39-46.
• [13]Deo RC, Wilson JG, Xing C, Lawson K, Kao WH, Reich D, Tandon A, Akylbekova E, Patterson N, Mosley TH Jr, et al.: Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One 2011, 6(1):e14581.
• [14]Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, Catanese JJ, Pullinger CR, Leong DU, Arellano AR, et al.: A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007, 27(9):2030-2036.
• [15]Ober C, Nord AS, Thompson EE, Pan L, Tan Z, Cusanovich D, Sun Y, Nicolae R, Edelstein C, Schneider DH, et al.: Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J Lipid Res 2009, 50(5):798-806.
• [16]Ronald J, Rajagopalan R, Cerrato F, Nord AS, Hatsukami T, Kohler T, Marcovina S, Heagerty P, Jarvik GP: Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke 2011, 42(1):2-9.
• [17]Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, et al.: Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361(26):2518-2528.
• [18]Koch W, Mueller JC, Schrempf M, Wolferstetter H, Kirchhofer J, Schomig A, Kastrati A: Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene. Ann Hum Genet 2013, 77(1):47-55.
• [19]Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, Jones GT, Van-Rij AM, Eapen DJ, Baas AF, et al.: Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 2012, 60(8):722-729.
• [20]Kraft HG, Kochl S, Menzel HJ, Sandholzer C, Utermann G: The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 1992, 90(3):220-230.
• [21]Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, Kelemen L, Yi C, Lonn E, Gerstein H, et al.: Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000, 356(9226):279-284.